{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:29:13Z","timestamp":1793734153786,"version":"4.6.1"},"reference-count":0,"publisher":"American Society of Hematology","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B-cell lymphoma (LBCL). Here, we aimed to assess survival and safety in ZUMA-1 after 5 years of follow-up. Eligible adults with refractory LBCL (diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma) received lymphodepleting chemotherapy followed by axi-cel infusion targeted at 2\u00d7106 cells\/kg. Investigator-assessed response, updated survival, safety, and pharmacokinetic outcomes were assessed in treated patients. The objective response rate in the 101 treated patients was 83% (58% complete response rate), and with a median follow-up of 63.1 months, responses were ongoing at data cutoff in 31%. Median overall survival (OS) was 25.8 months and the estimated 5-year OS rate was 42.6%. Disease-specific survival (excluding deaths unrelated to disease progression) estimated at 5 years was 51.0%. No new serious adverse events or deaths related to axi-cel were observed after additional follow-up. Peripheral blood B cells were detectable in all evaluable patients at 3 years with polyclonal B-cell recovery in 91%. Ongoing responses at 60 months were associated with early CAR T-cell expansion. In conclusion, this 5-year follow-up analysis of ZUMA-1 demonstrates sustained overall and disease-specific survival, with no new safety signals in patients with refractory LBCL. Protracted B-cell aplasia was not required for durable responses. These findings support the curative potential of axi-cel in a subset of patients with aggressive B-cell lymphomas. ClinicalTrials.gov, number NCT02348216<\/jats:p>","DOI":"10.1182\/blood.2022018893","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T19:57:09Z","timestamp":1677182229000},"update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":152,"title":["5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)"],"prefix":"10.1182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-4914","authenticated-orcid":false,"given":"Sattva S.","family":"Neelapu","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8848-8474","authenticated-orcid":false,"given":"Armin","family":"Ghobadi","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis, St. Louis, Missouri, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-4305","authenticated-orcid":false,"given":"David B","family":"Miklos","sequence":"additional","affiliation":[{"name":"Stanford University Medical School, Stanford, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaros J.","family":"Lekakis","sequence":"additional","affiliation":[{"name":"University of Miami, Miami, Florida, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-9641","authenticated-orcid":false,"given":"Olalekan O.","family":"Oluwole","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Braunschweig","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute, New Brunswick, New Jersey, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Timmerman","sequence":"additional","affiliation":[{"name":"UCLA School of Medicine, Los Angeles, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-8871","authenticated-orcid":false,"given":"Abhinav","family":"Deol","sequence":"additional","affiliation":[{"name":"Wayne State University, Detroit, Michigan, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Reagan","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center, Rochester, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8265-9340","authenticated-orcid":false,"given":"Patrick Joseph","family":"Stiff","sequence":"additional","affiliation":[{"name":"Loyola University Medical Center, Maywood, Illinois, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-290X","authenticated-orcid":false,"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute, Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7891-9891","authenticated-orcid":false,"given":"Umar","family":"Farooq","sequence":"additional","affiliation":[{"name":"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5125-6522","authenticated-orcid":false,"given":"Andre","family":"Goy","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center, Hackensack, New Jersey, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McSweeney","sequence":"additional","affiliation":[{"name":"Colorado Blood Cancer Institute, Denver, Colorado, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9060-8911","authenticated-orcid":false,"given":"Javier","family":"Munoz","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"City Of Hope National Medical Center, Duarte, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, Florida, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center, Duarte, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian A.","family":"Bot","sequence":"additional","affiliation":[{"name":"Capstan Therapeutics, Santa Monica, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhine R.","family":"Shen","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghui","family":"Dong","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwarjit","family":"Singh","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Miao","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny J.","family":"Kim","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company, Santa Monica, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, Florida, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,2,23]]},"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2022018893\/2035688\/blood.2022018893.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2022018893\/2035688\/blood.2022018893.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T19:57:13Z","timestamp":1677182233000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/doi\/10.1182\/blood.2022018893\/494672\/5-Year-Follow-Up-Supports-Curative-Potential-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1182\/blood.2022018893","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"article-number":"blood.2022018893"}}